# A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)

> **NCT00686595** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 48 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **BIOLOGICAL:** Infliximab

## Key facts

- **NCT ID:** NCT00686595
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10-01
- **Primary completion:** 2009-10-01
- **Final completion:** 2009-10-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686595, "A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00686595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*